Generic Ivermectin ( Ivermectin )

Order cheap Generic Ivermectin (Ivermectin) without dr prescription in the United States

In our USA pharmacy, you can buy Ivermectin without a prescription, with delivery across the USA within 2‑5 days. Discreet and anonymous packaging.
Ivermectin is an antiparasitic agent that binds selectively to glutamate‑gated chloride ion channels in invertebrate nerve and muscle cells, causing hyperpolarization, paralysis, and death of the parasite. It is used to treat certain parasitic roundworm infections, including strongyloidiasis of the intestinal tract and onchocerciasis (river blindness), and may also be used off‑label for other parasitic conditions.
Usual adult dose: For strongyloidiasis, a single oral dose of 200 mcg per kilogram of body weight. For onchocerciasis, a single oral dose of 150 mcg per kilogram of body weight, repeated every 6‑12 months until symptoms resolve. Dosing is based on body weight; common tablet strengths include 3 mg, 6 mg, and 12 mg, so a 60‑kg adult would typically take two 6‑mg tablets for strongyloidiasis.
Dosage form: Oral tablets (3 mg, 6 mg, 12 mg).
Onset of action: Antiparasitic effects begin within hours of administration; microfilariae levels in onchocerciasis are reduced within days, though adult worm death may take weeks to months.
Duration of action: A single dose is often curative for strongyloidiasis; for onchocerciasis, repeated doses every 6‑12 months are required to suppress microfilariae.
Alcohol consumption should be moderate; heavy intake may increase the risk of central nervous system side effects such as dizziness or drowsiness, and may worsen liver function in susceptible individuals.
Most common side effects: headache, dizziness, nausea, diarrhea, and itching; in onchocerciasis, a transient worsening of skin symptoms (Mazzotti reaction) may occur due to dying microfilariae.
Would you like to try Ivermectin without a prescription?

General Information about Ivermectin

• INN (International Nonproprietary Name): Ivermectin
• Brand names available in the USA: Stromectol® (Merck & Co., Inc.). Generic ivermectin tablets are manufactured by Teva Pharmaceuticals USA, Inc., Edenbridge Pharmaceuticals, LLC, and others.
• ATC code: P02CF01 (ivermectin for oral administration)
• Dosage forms and strengths: Oral tablets containing 3 mg, 6 mg, or 12 mg of ivermectin.
• Manufacturers in USA: Merck & Co., Inc. (brand Stromectol®); generic manufacturers include Teva Pharmaceuticals USA, Inc., Edenbridge Pharmaceuticals, LLC, and other FDA‑approved producers.
• Registration status in USA: Approved by the U.S. Food and Drug Administration (FDA) on November 22, 1996 (NDA 020742).
• OTC / Rx classification: Prescription only (Rx).

Mechanism of Action and Pharmacology

Ivermectin is a semisynthetic macrocyclic lactone derived from avermectins, which are fermentation products of the soil bacterium Streptomyces avermitilis. Its primary mechanism of action involves potent, selective, and high‑affinity binding to glutamate‑gated chloride ion channels (GluCls) present in invertebrate nerve and muscle cells. This binding increases the permeability of the cell membrane to chloride ions, leading to hyperpolarization of the cell, which results in paralysis and death of the parasite. Ivermectin also interacts with gamma‑aminobutyric acid (GABA)‑gated chloride channels in nematodes, further contributing to its anthelmintic effect. In mammals, GABA‑gated channels are primarily found in the central nervous system, and ivermectin does not readily cross the blood‑brain barrier due to the activity of the P‑glycoprotein (P‑gp) efflux transporter; thus, therapeutic doses in humans exhibit limited neurotoxicity. Following oral administration, peak plasma concentrations are reached in approximately 4 hours. Ivermectin is highly protein‑bound (approximately 93%) and undergoes extensive hepatic metabolism via CYP3A4. The elimination half‑life is approximately 18 hours. It is excreted almost exclusively in the feces, with less than 1% appearing in the urine.

Indications

• Treatment of intestinal strongyloidiasis (infection with Strongyloides stercoralis).
• Treatment of onchocerciasis (river blindness) caused by Onchocerca volvulus; note that ivermectin does not kill adult worms but reduces microfilarial burden and prevents disease progression.
• Off‑label uses (evidence‑supported): treatment of scabies (particularly crusted scabies), pediculosis (lice), cutaneous larva migrans, gnathostomiasis, and various other helminthic infections. Not approved for prevention or treatment of COVID‑19; the FDA and major health organizations strongly advise against this use outside of clinical trials.

Important Warnings and Precautions

Ivermectin may cause serious neurologic adverse events, particularly in patients with high‑burden Loa loa coinfection, where rapid microfilarial killing can lead to severe encephalopathy (Mazzotti reaction). In the treatment of onchocerciasis, worsening skin reactions, eye inflammation, and systemic symptoms may occur as microfilariae die; these reactions are usually manageable with supportive care. Patients with compromised blood‑brain barrier function (e.g., active meningitis, human African trypanosomiasis) may be at increased risk of CNS toxicity. Concomitant use of ivermectin with other drugs that are strong P‑gp inhibitors or CYP3A4 inhibitors may increase systemic exposure and neurotoxicity risk. Ivermectin is not recommended during pregnancy, especially during the first trimester. Breastfeeding women should use only if clearly needed. In mass drug administration programs for onchocerciasis, periodic ophthalmologic examinations are recommended. In immunocompromised patients, multiple doses may be required for strongyloidiasis; however, ivermectin is generally well‑tolerated.

At‑risk groups

• Elderly: No dose adjustment is recommended based solely on age; however, elderly patients may be at higher risk of CNS effects due to potential age‑related blood‑brain barrier changes. Clinical monitoring is advised.
• Pregnancy: Ivermectin is pregnancy Category C. Animal studies have shown adverse fetal effects. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Mass administration programs in endemic areas have not shown a definitive increase in adverse pregnancy outcomes, but caution is warranted, especially in the first trimester.
• Breastfeeding: Ivermectin is excreted into human milk in small amounts. A single dose is considered compatible with breastfeeding by the American Academy of Pediatrics; however, repeated or high‑dose regimens should be used only if the benefit outweighs the risk, and the infant should be monitored for sedation, poor feeding, or lethargy.
• Renal impairment: No dose adjustment is required for mild to moderate renal impairment. Data are limited in severe renal impairment and end‑stage renal disease; use with caution.
• Hepatic impairment: Ivermectin is extensively metabolized by the liver; patients with significant hepatic dysfunction may have reduced clearance. No specific dose adjustment guidelines exist, but monitoring for toxicity is recommended.
• Pediatric: Ivermectin is approved for children weighing 15 kg or more for the treatment of intestinal strongyloidiasis and onchocerciasis. Dosing is weight‑based. Safety and efficacy in children weighing less than 15 kg have not been established.
• Immunocompromised patients: Hyperinfection syndrome with strongyloidiasis may require prolonged or repeated courses; ivermectin is the drug of choice, but veterinary formulations should never be used in humans.
• Loa loa coinfection: Risk of severe encephalopathy; ivermectin should be used with extreme caution in patients with high Loa loa microfilaremia.

Driving and alcohol

Ivermectin can cause dizziness, somnolence, and visual disturbances, which may impair the ability to drive or operate machinery. Patients should avoid driving or hazardous activities until they know how the medication affects them. Alcohol consumption should be limited; alcohol may exacerbate dizziness and drowsiness, and heavy intake may increase the risk of liver toxicity.

Dosage Instructions

• Intestinal strongyloidiasis: A single oral dose of 200 mcg per kilogram of body weight, taken on an empty stomach with a full glass of water. Fasting for at least 2 hours before and after the dose is recommended. For patients with hyperinfection syndrome, repeated or extended courses may be necessary; consult an infectious disease specialist.
• Onchocerciasis: A single oral dose of 150 mcg per kilogram of body weight, taken on an empty stomach with water. Doses are repeated every 6‑12 months until adult worm activity ceases and symptoms resolve. Because ivermectin kills microfilariae but not adult worms, retreatment is essential to control the infection.
• Scabies (off‑label): A single dose of 200 mcg per kilogram, often repeated in 1‑2 weeks, especially for crusted (Norwegian) scabies where multiple doses may be required in combination with topical agents.
• Dosing by weight: Use actual body weight. For example, a 60‑kg person would receive 12 mg (two 6‑mg tablets) for strongyloidiasis, or 9 mg (one 9‑mg dose, typically using three 3‑mg tablets) for onchocerciasis. Tablets are available as 3 mg, 6 mg, and 12 mg; combine strengths to achieve the correct total dose.
• Administration: Take on an empty stomach at least 1 hour before or 2 hours after a meal. Swallow tablets whole with a full glass of water; do not crush or chew. For patients who cannot swallow whole tablets, crushing and mixing with food may be considered, but bioavailability may be altered; the FDA labeling recommends taking on an empty stomach for optimal absorption.
• Missed dose: Since treatment is usually a single dose, missing a dose is unlikely. If a dose is missed in a multi‑dose regimen, take it as soon as remembered and consult the prescribing physician for further instructions. Do not double doses.

Side Effects and Contraindications

Most common side effects (in strongyloidiasis): Headache (3%), dizziness (3%), nausea (2%), diarrhea (2%), and pruritus (3%). These are usually mild and transient.
Onchocerciasis‑related Mazzotti reaction (frequency varies): Fever, urticaria, pruritus, rash, lymphadenitis, myalgia, tachycardia, and hypotension. Ocular reactions include conjunctivitis, limbitis, corneal opacities, and chorioretinitis. These reactions are due to the killing of microfilariae and are not directly toxic effects of ivermectin; they may be managed with antipyretics, antihistamines, and corticosteroids in severe cases.
Serious adverse reactions: Neurologic events including encephalopathy (especially in Loa loa coinfection), coma, and seizure; hypotension; hepatitis; and severe skin reactions (toxic epidermal necrolysis, Stevens‑Johnson syndrome – rare). Elevated liver enzymes have been reported.
Absolute contraindications: Known hypersensitivity to ivermectin or any component of the formulation. There are no other absolute contraindications, but caution is required in patients with Loa loa infection, active meningitis, or blood‑brain barrier disruption.

Drug Interactions

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir): May significantly increase ivermectin plasma levels, potentially increasing neurotoxicity risk. Concomitant use should be avoided or closely monitored; a dose reduction of ivermectin may be considered.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort): May reduce ivermectin exposure and decrease efficacy. Monitor therapeutic response and consider dose adjustment.
• P‑glycoprotein (P‑gp) inhibitors (e.g., verapamil, cyclosporine, quinidine): Ivermectin is a P‑gp substrate; co‑administration may increase central nervous system penetration and toxicity. Use with caution.
• Warfarin: Ivermectin has been reported to potentiate the anticoagulant effect of warfarin; monitor INR closely and adjust warfarin dose as needed.
• Alcohol: May enhance CNS depressant effects; patients should limit alcohol intake during treatment.
• Other antiparasitic agents: No clinically significant pharmacokinetic interactions have been reported with albendazole, mebendazole, or praziquantel; combination therapy may be used for certain infections under specialist guidance.

Practical Advice

• Take ivermectin exactly as prescribed. The dose is determined by your body weight; be sure the correct number of tablets is dispensed.
• Take the medication on an empty stomach with a full glass of water, at least 1 hour before or 2 hours after a meal. Fasting improves absorption and efficacy.
• If you are being treated for onchocerciasis, understand that a worsening of itching, rash, lymph node swelling, or eye discomfort may occur within the first few days after taking the dose. This is a normal reaction to dying parasites and may be managed with over‑the‑counter antihistamines or acetaminophen unless severe; contact your healthcare provider if symptoms are intolerable.
• For strongyloidiasis, a single dose is usually sufficient, but you may be asked to provide stool samples a few weeks later to confirm cure. In immunocompromised patients, additional doses may be required.
• Avoid driving or operating machinery until you see how ivermectin affects you. Dizziness and drowsiness can occur.
• Limit alcohol consumption during treatment.
• Inform your healthcare provider about all medications, supplements, and herbal products you are taking, particularly ketoconazole, itraconazole, clarithromycin, rifampin, verapamil, or warfarin.
• Store tablets at room temperature (20‑25°C / 68‑77°F) in a dry place, protected from light. Keep out of reach of children.
• Never self‑medicate with veterinary formulations of ivermectin; they are highly concentrated and can cause severe toxicity in humans.
• If you miss a dose (for multi‑dose regimens), contact your healthcare provider. Do not take extra tablets to make up for a missed dose.

Alternative Medications

• Albendazole (Albenza®): A benzimidazole anthelmintic with a broad spectrum of activity. Often used as an alternative for strongyloidiasis and other intestinal nematodes. However, ivermectin is generally considered superior for strongyloidiasis.
• Moxidectin (Filsuvez®? Not exactly; moxidectin is approved for onchocerciasis in some countries, not yet FDA‑approved for human use as an oral tablet as of 2024. But we can mention it as an alternative not yet in US). Better to use alternatives approved in the US. For scabies, topical permethrin or oral ivermectin; for strongyloidiasis, albendazole is an alternative. For onchocerciasis, ivermectin is the only approved treatment; doxycycline is used to target Wolbachia endosymbionts but is slow.
• Albendazole (Albenza®): For strongyloidiasis and other helminth infections, though less effective than ivermectin for Strongyloides.
• Permethrin cream 5% (Elimite®): Topical treatment for scabies; often used in combination with oral ivermectin for crusted scabies.
• Doxycycline: Used over a 4‑6 week course to target Wolbachia bacteria within Onchocerca volvulus, which leads to long‑term sterilization of adult worms. May be used as an adjunct to ivermectin.
• Diethylcarbamazine (DEC): Not available in the US; formerly used for lymphatic filariasis and onchocerciasis but contraindicated in onchocerciasis due to severe Mazzotti reactions.

Clinical Efficacy

Ivermectin's efficacy for strongyloidiasis was established in clinical trials demonstrating cure rates of >90% after a single oral dose of 200 mcg/kg, with significant improvement in symptoms and clearance of larvae from stool. For onchocerciasis, annual or semiannual mass drug administration with ivermectin has dramatically reduced the prevalence of skin and ocular disease in endemic areas; microfilarial loads decrease by 90‑95% within days, though adult worms are not killed, necessitating repeated doses over the 10‑15 year lifespan of the parasite. Ivermectin has been used safely in hundreds of millions of people globally, earning it a place on the World Health Organization's List of Essential Medicines. In scabies, a single dose of 200 mcg/kg, often repeated after 1‑2 weeks, provides cure rates of 70‑90%, comparable to topical permethrin. In crusted scabies, combined oral ivermectin and topical agents are standard. The drug has shown in vitro activity against various viruses, including SARS‑CoV‑2, but rigorous clinical trials have not demonstrated a benefit for COVID‑19, and the FDA advises against its use for this purpose outside of approved clinical studies.

Important:

Ivermectin is a prescription antiparasitic medication that must be used exactly as directed by a qualified healthcare provider. The dose is based on your body weight, and the correct tablet strength must be dispensed to achieve the appropriate dose. Do not use ivermectin to treat or prevent COVID‑19; it is not authorized for this purpose, and misuse can lead to serious harm. If you are being treated for onchocerciasis, be aware that a temporary worsening of itching, rash, or eye problems may occur as the parasites die; contact your doctor if these symptoms are severe. Ivermectin can cause dizziness and drowsiness; do not drive or operate machinery until you know how it affects you. Avoid alcohol during treatment. If you have a history of meningitis, a compromised blood‑brain barrier, or are taking medications such as ketoconazole, ritonavir, or verapamil, inform your healthcare provider, as these may increase the risk of neurotoxicity. Pregnant or breastfeeding women should discuss risks with their physician. Keep this medicine out of reach of children. Do not take veterinary ivermectin products; they are not safe for human use and can cause severe toxicity, including seizures and death. In the event of an overdose, seek emergency medical attention immediately.

How to buy Generic Ivermectin no prescription U.S. Online Pharmacy